Fosfomycin—an ‘old’ antibiotic that was developed more than 40 years ago—is a broad spectrum antibiotic that inhibits the early stages of the bacterial cell wall synthesis.
“Importantly, we show that there is a viable alternative to the lengthy and thus costly development of new antibiotics. The often scattered knowledge in literature and in the clinic is waiting to be combined and can be used immediately in a confirmatory clinical trial,” said senior author Dr. Jasper Stevens, of the University Medical Center Groningen, in The Netherlands.
Full bibliographic information:
Natalia V. Ortiz Zacaras, Anneke C. Dijkmans, Jacobus Burggraaf, Johan W. Mouton, Erik B. Wilms, Cees van Nieuwkoop, Daan J. Touw, Ingrid M. C. Kamerling and Jasper Stevens. Fosfomycin as a potential therapy for the treatment of systemic infections: a population pharmacokinetic model to simulate multiple dosing regimens. Pharmacology Research & Perspectives.